- In July 2025, Cipla reaffirmed its commitment to fighting antimicrobial resistance by investing in novel antibiotic R&D for high-burden infections such as community-acquired pneumonia. The company is also working to increase access to generics for underserved populations
- In January 2025, Wockhardt received marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) for Miqnaf (Nafithromycin), following successful Phase III trials in India. This marks a key milestone in India’s efforts to combat antibiotic resistance in pneumonia treatment
- In November 2024, Wockhardt launched Nafithromycin (brand name: Miqnaf), India’s first indigenous macrolide antibiotic developed to treat community-acquired bacterial pneumonia (CABP). This launch strengthens India’s self-reliance in developing advanced antibiotics and contributes significantly to the domestic CAP treatment space
- In September 2023, Astrazeneca has received an approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market a medication to prevent Respiratory Syncytial virus. This will help the company to strengthen its presence in India market
- In May 2021, Teva Pharmaceutical Industries Ltd. announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the Reference Listed Drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. This has helped the company to strengthen its product portfolio
- In May 2021, Teva Pharmaceutical Industries Ltd. announced the U.S. launch of its generic erythromycin tablets (250 mg and 500 mg), a therapeutic equivalent to the Reference Listed Drug (RLD) by Arbor Pharmaceuticals. While this development was for the U.S. market, it contributes to the global supply chain and could support access to CAP treatments in India via export pathways
